AbbVie Announces European Commission Approval of SKYRIZI® (risankizumab) for the Treatment of Adults with Moderately to Severely Active Ulcerative Colitis

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. ACN
3. NVDA
4. GOOGL
5. MU
6. DFTX
7. USO
8. APGE
9. ABBV
10. NAVN

Go back to AbbVie Announces European Commission Approval of SKYRIZI® (risankizumab) for the Treatment of Adults with Moderately to Severely Active Ulcerative Colitis

Abbvie (ABBV) PT Raised to $200 at Goldman Sachs

July 26, 2024 5:53 AM EDT

Goldman Sachs analyst Chris Shibutani raised the price target on Abbvie (NYSE: ABBV) to $200.00 (from $190.00) while maintaining a Buy rating.

The analyst comments "Even amidst expectations that Immunology would once again deliver, we see basis for the factors underpinning growth for both Skyrizi and Rinvoq to continue propelling upside - including NBRx dynamics that... More

William Blair Reiterates Outperform Rating on Abbvie (ABBV)

July 26, 2024 5:37 AM EDT

William Blair analyst Tim Lugo reiterated an Outperform rating on Abbvie (NYSE: ABBV).

The analyst comments "Stock thoughts: We believe AbbVie has a strong and durable growth profile over the coming years thanks to its strong growth platform, recently augmented by the... More